- Business Strategies
- BMS sells 15% of Mead through IPO that nets $684mm
- BMS and Otsuka develop and sell schizophrenia drug
- BMS partners Sprycel and Ixempra with Otsuka
- BMS takes over antibody platform company Medarex for $2bn
- BMS and Medarex sign an anticancer deal
- BMS sells medical imaging unit to equity firm Avista for $525mm
- Avista, Nordic buy BMS's wound care unit ConvaTec for $4.1bn
- Lilly comes out on top with $70/share ImClone bid
- AZ and BMS enter Type II diabetes deal; BMS later sells diabetes business to AZ
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.